Abstract
Hepatitis C virus (HCV) infection is characterized by a number of autoreactive manifestations, such as autoantibody production, cryoglobulinemia and thyroid disorders. We will analyse critically the mechanisms invoked, and partially documented, to explain such manifestations arising in genetically predisposed individuals exposed to HCV. In particular we will examine the available evidence implicating the virus in lowering the B cell activation threshold, in directly infecting lymphocytes and in inducing self-reactivity through a mechanism of molecular mimicry. We will then move to the HCV related clinical immunopathological manifestations, with a specific attention to the effects of antiviral treatment.
Keywords: Hepatitis C virus, immune system dysregulation, molecular mimicry, antiviral therapy
Current Pharmaceutical Design
Title: HCV and Autoimmunity
Volume: 14 Issue: 17
Author(s): S. Ferri, L. Muratori, M. Lenzi, A. Granito, F. B. Bianchi and D. Vergani
Affiliation:
Keywords: Hepatitis C virus, immune system dysregulation, molecular mimicry, antiviral therapy
Abstract: Hepatitis C virus (HCV) infection is characterized by a number of autoreactive manifestations, such as autoantibody production, cryoglobulinemia and thyroid disorders. We will analyse critically the mechanisms invoked, and partially documented, to explain such manifestations arising in genetically predisposed individuals exposed to HCV. In particular we will examine the available evidence implicating the virus in lowering the B cell activation threshold, in directly infecting lymphocytes and in inducing self-reactivity through a mechanism of molecular mimicry. We will then move to the HCV related clinical immunopathological manifestations, with a specific attention to the effects of antiviral treatment.
Export Options
About this article
Cite this article as:
Ferri S., Muratori L., Lenzi M., Granito A., Bianchi B. F. and Vergani D., HCV and Autoimmunity, Current Pharmaceutical Design 2008; 14 (17) . https://dx.doi.org/10.2174/138161208784746824
DOI https://dx.doi.org/10.2174/138161208784746824 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases
Current Radiopharmaceuticals Adverse Cutaneous Reactions of Systemic Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Use of Interferons in Respiratory Diseases
Current Respiratory Medicine Reviews Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications
Coronaviruses Glucocorticoids and Vascular Reactivity
Current Vascular Pharmacology Vasculitis: Decade in Review
Current Rheumatology Reviews Pattern of Primary Vasculitis with Peripheral Ischemic Manifestations: Report of a Case Series and Role of Vascular Surgery
Current Rheumatology Reviews Role of DAP12 in Innate and Adaptive Immune Responses
Current Pharmaceutical Design Postoperative Care of the Transplanted Patient
Current Cardiology Reviews Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Role of Invariant Natural Killer T (iNKT) Cells in Systemic Lupus Erythematosus
Current Medicinal Chemistry Review of the Biological Activity of Maslinic Acid
Current Drug Targets PD1/PD-L1 Axis in Uro-oncology
Current Drug Targets Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery
Current Pharmaceutical Design Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions
Current Protein & Peptide Science Interleukin-21 in Immune and Allergic Diseases
Inflammation & Allergy - Drug Targets (Discontinued)